Patents Represented by Attorney Sophie Binet Cross
-
Patent number: 8314148Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-9, and/or MMP-12 and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.Type: GrantFiled: May 11, 2012Date of Patent: November 20, 2012Assignee: Novartis AGInventors: Thomas Leutert, Jonathan E. Grob, Ruben Alberto Tommasi, Erin Keaney, Ayako Honda
-
Patent number: 8263629Abstract: The present invention provides a compound of formula I?; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: GrantFiled: May 27, 2010Date of Patent: September 11, 2012Assignee: Novartis AGInventors: Gary Mark Coppola, Yuki Iwaki, Rajeshri Ganesh Karki, Toshio Kawanami, Gary Michael Ksander, Muneto Mogi, Robert Sun
-
Patent number: 8232403Abstract: The present invention relates to novel compounds of formula (I) or a pharmaceutical composition thereof, with all the variables being defined in the text. The present invention further relates to the use of the compounds herein for treatment of or delay progression to overt to diseases in which CETP is involved.Type: GrantFiled: May 8, 2007Date of Patent: July 31, 2012Assignee: Novartis AGInventors: Masashi Kishida, Naoko Matsuura, Hidetomo Imase, Yuki Iwaki, Ichiro Umemura, Osamu Ohmori, Eiji Kawahara
-
Patent number: 8232427Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-9, and/or MMP-12 and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.Type: GrantFiled: March 27, 2007Date of Patent: July 31, 2012Assignee: Novartis AGInventors: Thomas Leutert, Jonathan E Grob, Ruben Alberto Tommasi, Erin E. Pusateri, Ayako Honda
-
Patent number: 8222286Abstract: The present invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R6, A1, A2, X1, s and m are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: GrantFiled: November 16, 2010Date of Patent: July 17, 2012Assignee: Novartis AGInventors: Yuki Iwaki, Toshio Kawanami, Gary Michael Ksander, Muneto Mogi
-
Patent number: 8222424Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.Type: GrantFiled: March 23, 2009Date of Patent: July 17, 2012Assignee: Novartis AGInventors: Claus Ehrhardt, Leslie Wighton McQuire, Pascal Rigollier, Olivier Rogel, Michael Shultz, Ruben Alberto Tommasi
-
Patent number: 8193349Abstract: The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.Type: GrantFiled: November 5, 2008Date of Patent: June 5, 2012Assignee: Novartis AGInventors: Muneto Mogi, Ken Yamada, Kayo Yasoshima, Toshio Kawanami, Ichiro Umemura, Yuki Iwaki, Hongbo Qin, Hidetomo Imase
-
Patent number: 8183366Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein the variants R, R9, Z, X, Q and Y are defined in the specification.Type: GrantFiled: September 20, 2010Date of Patent: May 22, 2012Assignee: Novartis AGInventors: Rene Hersperger, Philipp Janser, Emil Pfenninger, Hans J Wuethrich, Wolfgang Miltz
-
Patent number: 8178559Abstract: 3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula (I), wherein the symbols have the meanings defined in the specification.Type: GrantFiled: July 6, 2011Date of Patent: May 15, 2012Assignee: Novartis AGInventors: Werner Breitenstein, Takeru Ehara, Claus Ehrhardt, Philipp Grosche, Yuko Hitomi, Yuki Iwaki, Takanori Kanazawa, Kazuhide Konishi, Juergen Klaus Maibaum, Keiichi Masuya, Atsuko Iwasaki, Nils Ostermann, Masaki Suzuki, Atsushi Toyao, Fumiaki Yokokawa
-
Patent number: 8178650Abstract: The present application relates to cyclic depsipeptides, or derivatives thereof, having the structure of formula (I), and uses thereof, e.g. as inhibitors of kallikrein 7 and human neutrophil elastase.Type: GrantFiled: August 18, 2008Date of Patent: May 15, 2012Assignee: Novartis AGInventors: Philipp Krastel, Brigitta-Maria Liechty, Josef Gottfried Meingassner, Esther Schmitt, Erwin Paul Schreiner
-
Patent number: 8163773Abstract: The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The preferred compounds (which can also be present as salts) have the formula I wherein R1, R2, T, R3 and R4 are as defined in the specification.Type: GrantFiled: July 10, 2006Date of Patent: April 24, 2012Assignee: Novartis AGInventors: Werner Breitenstein, Claus Erhardt, Juergen Klaus Maibaum, Nils Ostermann, Juerg Zimmermann, Keiichi Masuya, Kazuhide Konishi, Fumiaki Yokokawa, Takanori Kanazawa, Edgar Jacoby, Andreas Marzinzik, Philipp Grosche, Shimpei Kawakami
-
Patent number: 8129411Abstract: The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds have the formula I? wherein R1, R2, T, R3 and R4 are as defined in the specification.Type: GrantFiled: December 28, 2006Date of Patent: March 6, 2012Assignee: Novartis AGInventors: Takeru Ehara, Philipp Grosche, Osamu Irie, Yuki Iwaki, Takanori Kanazawa, Shimpei Kawakami, Kazuhide Konishi, Muneto Mogi, Masaki Suzuki, Fumiaki Yokokawa
-
Patent number: 8119617Abstract: The present invention relates to compounds of formula wherein the residues have various meanings and their use as pharmaceuticals.Type: GrantFiled: August 21, 2007Date of Patent: February 21, 2012Assignee: Novartis AGInventors: Karl Baumann, Andreas Billich, Berndt Oberhauser
-
Patent number: 8084450Abstract: 3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4-substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed.Type: GrantFiled: December 28, 2005Date of Patent: December 27, 2011Assignee: Novartis AGInventors: Werner Breitenstein, Takeru Ehara, Claus Ehrhardt, Philipp Grosche, Yuko Hitomi, Yuki Iwaki, Takanori Kanazawa, Kazuhide Konishi, Juergen Klaus Maibaum, Keiichi Masuya, Atsuko Nihonyanagi, Nils Ostermann, Masaki Suzuki, Atsushi Toyao, Fumiaki Yokokawa
-
Patent number: 8030334Abstract: The present invention provides novel organic compounds of Formula I: methods of use, and pharmaceutical compositions thereof.Type: GrantFiled: June 26, 2009Date of Patent: October 4, 2011Assignee: Novartis AGInventors: Christopher Adams, Qi-Ying Hu, Leslie Wighton McQuire, Julien Papillon
-
Patent number: 7919529Abstract: Disclosed are ?-amino-?-hydroxy-?-aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.Type: GrantFiled: June 12, 2009Date of Patent: April 5, 2011Assignee: Novartis AGInventors: Daniel Kaspar Baeschlin, Juergen Klaus Maibaum, Holger Sellner
-
Patent number: 7858781Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof, wherein the variants R, R9, Z, X, Q and Y are defined in the specification.Type: GrantFiled: February 10, 2005Date of Patent: December 28, 2010Assignee: Novartis AGInventors: René Hersperger, Philipp Janser, Emil Pfenninger, Hans Juerg Wuethrich, Wolfgang Miltz
-
Patent number: 7851642Abstract: Disclosed are ?-amino-?-hydroxy-?-aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.Type: GrantFiled: June 12, 2009Date of Patent: December 14, 2010Assignee: Novartis AGInventors: Daniel Kaspar Baeschlin, Juergen Klaus Maibaum, Holger Sellner
-
Patent number: 7838674Abstract: The present invention describes tetracyclic compounds of formula (IA) or (IB), wherein the symbols R, X, A, Y, R2, R3 and D are as defined in the specification, their use in the treatment of certain diseases, e.g. depending on MK-2 or TNF activity, and ways of manufacturing them.Type: GrantFiled: July 16, 2008Date of Patent: November 23, 2010Assignee: Novartis AGInventors: Achim Schlapbach, Laszlo Revesz, Guido Koch
-
Patent number: 7807709Abstract: The invention relates to the use of (3,4-di-, 3,3,4-tri, 3,4,4-tri- or 3,3,4,4-tetra-)substituted pyrrolidine compounds for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; compounds that are part of a subclass of these substituted pyrrolidine compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; new compounds that are part of a subclass of these substituted pyrrolidine compounds; pharmaceutical formulations comprising said substituted pyrrolidine compounds, and/or a method of treatment comprising administering said substituted pyrrolidine compounds, a method for the manufacture especially of said new substituted pyrrolidine compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesisType: GrantFiled: March 21, 2006Date of Patent: October 5, 2010Assignee: Novartis AGInventors: Claus Ehrhardt, Osamu Irie, Edwige Liliane Lorthiois, Juergen Klaus Maibaum, Nils Ostermann, Holger Sellner